RT for Breast Cancer Patients Is 'Less Scary' Than Anticipated

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video examines patient fears and misconceptions regarding radiation therapy for the treatment of breast cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Narek Shaverdian, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, discusses results of a study that surveyed patients to examine fears and misconceptions regarding radiation therapy for the treatment of breast cancer.

      Shaverdian presented the results of the study (abstract 85) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held last month in San Diego.

      Recent Videos
      Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
      Further Research May Explore Systemic Therapy Failure Following RT in NSCLC
      Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
      Data Show Increasing Systemic Therapy Use in NSCLC Radiotherapy Population
      Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
      Reflexology Program May Have Use in Integrative Breast Cancer Care
      A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
      ctDNA Data in Gynecologic Cancer RT Population May Be Hypothesis-Generating
      Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
      Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC
      ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
      ctDNA Clearance Confers Responses to Radiation in Gynecologic Malignancies
      Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
      Assessing ctDNA as a Predictor of RT Responses in Gynecologic Cancers
      Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
      Reflexology Reduces Stress/Pain, Increases Energy During Breast Cancer RT
      Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
      Evaluating Reflexology Impact on Breast Cancer RT-Related Anxiety, Pain
      Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
      RT May Affect Scholastic Performance in Pediatric Brain Tumor Survivors
      Related Content
      ASTRO Guideline Recommends EBRT for Symptomatic Bone Metastases

      ASTRO Guideline Recommends EBRT for Symptomatic Bone Metastases

      Tim Cortese
      November 28th 2024
      Article

      ASTRO assembled a task force to create a guideline for the administration of palliative external beam radiation therapy for patients with symptomatic bone metastases.

      Offering certain radiotherapy modalities based on disease burden may play a role in the outcomes of those with ES-SCLC, according to James Ninia, MD.

      Complete Consolidative Radiotherapy May Have Survival Benefits in ES-SCLC

      Russ Conroy
      October 19th 2024
      Article

      Offering certain radiotherapy modalities based on disease burden may play a role in the outcomes of those with ES-SCLC, according to James Ninia, MD.

      Results showed of the phase 3 ADRIATIC study found that treatment with durvalumab elicited similar radiation pneumonitis incidences vs placebo for LS-SCLC.

      Durvalumab Shows Manageable Safety Profile in LS-SCLC

      Roman Fabbricatore
      October 10th 2024
      Article

      Results showed of the phase 3 ADRIATIC study found that treatment with durvalumab elicited similar radiation pneumonitis incidences vs placebo for LS-SCLC.

      Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.

      Nivolumab/RT Improves Biochemical Recurrence Outcomes in Prostate Cancer

      Russ Conroy
      October 4th 2024
      Article

      Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.

      Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

      Neoadjuvant Sotigalimab Proves Efficacious in Rectal Cancer

      Ariana Pelosci
      October 3rd 2024
      Article

      Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

      Data show that twice-daily radiotherapy may confer improved survival vs once-daily radiation in patients with limited-stage small cell lung cancer.

      Concurrent Chemoradiation/Atezolizumab Does Not Improve Survival in LS-SCLC

      Russ Conroy
      October 3rd 2024
      Article

      Data show that twice-daily radiotherapy may confer improved survival vs once-daily radiation in patients with limited-stage small cell lung cancer.